Annemieke M. Boot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Annemieke M. Boot has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- A. Emile J. Hendriks
Department of Pediatrics, Division of Endocrinology, Erasmus Medical Center-Sophia, Room Sp3435, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
2 shared publications Huibert A. P. Pols
Department of Internal Medicine III, Dijkzigt Hospital, Erasmus University, Rotterdam
2 shared publicationsS. L. S. Drop
Division of Endocrinology, Department of Pediatrics (A.E.J.H., S.L.S.D.), Erasmus Medical Center-Sophia; and Division of Reproductive Medicine, Department of Obstetrics and Gynecology (J.S.E.L.), Erasmus Medical Center, Rotterdam; and Department of Pediatric Endocrinology (A.M.B.), University Medical Center Groningen, Groningen, the Netherlands
2 shared publicationsAnita C. S. Hokken‐Koelega
Division of Endocrinology
1 shared publicationE P Krenning
Department of Pediatrics, Erasmus University, Rotterdam, Netherlands
1 shared publicationE.B. Wolvius
Oral and Maxillofacial Surgery, Erasmus MC, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- 1 January 2013
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 68 (1) , 36-37
Fertility of Tall Girls Treated With High-Dose Estrogen, A Dose-Response Relationship
High-dose estrogen treatment has been widely used to reduce the adult final height of tall girls. Women treated in childhood with high-dose estrogen are at increased risk of infertility later in life. It is unclear whether there is a dose-response relationship for estrogen on the fertility outcome of these women. The aim of this retrospective cohort study was to evaluate whether there is a dose-response relationship for estrogen treatment of tall girls and fertility in later life. Participants were 125 tall women aged 20 to 42 years, who had sought medical attention at a university medical center during childhood for their tall stature. Among these women, 52 had been treated with 100 μg and 43 with 200 μg of ethinyl estradiol (EE) in childhood. The control group was composed of 30 untreated women. The primary study outcomes were time to first pregnancy, treatment for infertility, and live birth rate. Treated women had an increased time to first pregnancy compared with untreated controls. Conception was achieved in 80% of untreated women within 1 year, but only 69% of women treated with 100 μg EE and 59% of women treated with 200 μg EE conceived in the first year. The observed trend of increased time to pregnancy with increased estrogen dose was significant (log-rank trend test, P = 0.01). Compared with no treatment, fecundity was reduced with both 100 μg EE (hazard ratio, 0.42; 95% confidence interval [CI], 0.19–0.95) and 200 μg EE (hazard ratio, 0.30; 95% CI, 0.13–0.72). There also was a significant trend in the incidence of infertility treatment for infertility with increased estrogen dose (P = 0.04). The odds of achieving at least 1 live birth was significantly reduced among women treated with 200 μg EE (odds ratio, 0.13; 95% CI, 0.02–0.81) but not in those treated with 100 μg EE. These findings show a dose-response relationship between dose used for the treatment of tall stature in adolescent girls and fertility in later life. A higher estrogen dose is associated with increased infertility.
- 1 January 2013
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 68 (1) , 36-37
Fertility of Tall Girls Treated With High-Dose Estrogen, A Dose-Response Relationship
High-dose estrogen treatment has been widely used to reduce the adult final height of tall girls. Women treated in childhood with high-dose estrogen are at increased risk of infertility later in life. It is unclear whether there is a dose-response relationship for estrogen on the fertility outcome of these women. The aim of this retrospective cohort study was to evaluate whether there is a dose-response relationship for estrogen treatment of tall girls and fertility in later life. Participants were 125 tall women aged 20 to 42 years, who had sought medical attention at a university medical center during childhood for their tall stature. Among these women, 52 had been treated with 100 μg and 43 with 200 μg of ethinyl estradiol (EE) in childhood. The control group was composed of 30 untreated women. The primary study outcomes were time to first pregnancy, treatment for infertility, and live birth rate. Treated women had an increased time to first pregnancy compared with untreated controls. Conception was achieved in 80% of untreated women within 1 year, but only 69% of women treated with 100 μg EE and 59% of women treated with 200 μg EE conceived in the first year. The observed trend of increased time to pregnancy with increased estrogen dose was significant (log-rank trend test, P = 0.01). Compared with no treatment, fecundity was reduced with both 100 μg EE (hazard ratio, 0.42; 95% confidence interval [CI], 0.19–0.95) and 200 μg EE (hazard ratio, 0.30; 95% CI, 0.13–0.72). There also was a significant trend in the incidence of infertility treatment for infertility with increased estrogen dose (P = 0.04). The odds of achieving at least 1 live birth was significantly reduced among women treated with 200 μg EE (odds ratio, 0.13; 95% CI, 0.02–0.81) but not in those treated with 100 μg EE. These findings show a dose-response relationship between dose used for the treatment of tall stature in adolescent girls and fertility in later life. A higher estrogen dose is associated with increased infertility.
- 1 December 2010
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (12) , 5233-5240
Fatherhood in Tall Men Treated with High-Dose Sex Steroids during Adolescence
Sex steroid treatment to reduce final height of tall boys has been available since the 1950s. In women, it has been shown to interfere with fertility. In men, no such data are available. We therefore evaluated fertility and gonadal function in tall men who did or did not receive high-dose androgen treatment in adolescence.
- 1 December 2010
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (12) , 5233-5240
Fatherhood in Tall Men Treated with High-Dose Sex Steroids during Adolescence
Sex steroid treatment to reduce final height of tall boys has been available since the 1950s. In women, it has been shown to interfere with fertility. In men, no such data are available. We therefore evaluated fertility and gonadal function in tall men who did or did not receive high-dose androgen treatment in adolescence.
- 1 November 1999
- Published by Elsevier in European Journal of Cancer
- Vol. 35 (12) , 1693-1697
Bone mineral density in children with acute lymphoblastic leukaemia
- 1 November 1999
- Published by Elsevier in European Journal of Cancer
- Vol. 35 (12) , 1693-1697
Bone mineral density in children with acute lymphoblastic leukaemia
- 1 November 1998
- Published by Wiley in Clinical Endocrinology
- Vol. 49 (5) , 665-672
Bone mineral density, bone metabolism and body composition of children with chronic renal failure, with and without growth hormone treatment
Osteopenia has been reported in adult patients with chronic renal failure (CRF). Only a few studies have been performed in children. The objective of this study was to evaluate bone mineral density (BMD), bone turnover, body composition in children with CRF and to study the effect of GH on these variables. Two groups were identified: patients with growth retardation who received GH (GH-group) and patients most of whom were not growth retarded who did not receive GH (no-GH-group). After an observation period of 6 months, the patients in the GH-group started GH treatment. Patients were studied every 6 months during 18 months. Thirty-six prepubertal patients (27 boys and 9 girls), mean age 7.9 years, with CRF participated in the study. The GH-group consisted of 17 patients of whom 14 completed one year treatment. The no-GH-group consisted of 19 patients, of whom 16 were followed for 6 months, 14 for 12 months and 13 for 18 months. Lumbar spine BMD, total body BMD and body composition were assessed by dual energy X-ray absorptiometry, compared to age-and sex-matched reference values of the same population and expressed as standard deviation scores (SDS). BMD of appendicular bone was measured by quantitative microdensitometry (QMD). Blood samples were obtained to assess bone metabolism and growth factors. Baseline mean lumbar spine and total body BMD SDS of all patients were not significantly different from normal. Mean lumbar spine and total body BMD SDS did not change significantly in the GH-group during GH treatment. The change of QMD at the midshaft during the first 6 months of GH treatment was significantly smaller than during the observation period (P < 0.01). Height SDS and biochemical markers of both bone formation and bone resorption increased significantly during GH treatment; 1,25-dihydroxyvitamin D remained stable. Lean tissue mass increased (P < 0.001) and percentage body fat decreased (P < 0.01) during GH treatment. BMD, the biochemical markers of bone turnover which are independent of renal function, and body composition remained stable in the no-GH-group. Mean lumbar spine and total body BMD of children with chronic renal failure did not differ from healthy controls. The lack of a GH-induced increase in 1,25-dihydroxyvitamin D levels, probably due to treatment with alpha-calcidol, might be linked to the absence of a response in BMD during GH treatment in children with chronic renal failure.
- 1 November 1998
- Published by Wiley in Clinical Endocrinology
- Vol. 49 (5) , 665-672
Bone mineral density, bone metabolism and body composition of children with chronic renal failure, with and without growth hormone treatment
Osteopenia has been reported in adult patients with chronic renal failure (CRF). Only a few studies have been performed in children. The objective of this study was to evaluate bone mineral density (BMD), bone turnover, body composition in children with CRF and to study the effect of GH on these variables. Two groups were identified: patients with growth retardation who received GH (GH-group) and patients most of whom were not growth retarded who did not receive GH (no-GH-group). After an observation period of 6 months, the patients in the GH-group started GH treatment. Patients were studied every 6 months during 18 months. Thirty-six prepubertal patients (27 boys and 9 girls), mean age 7.9 years, with CRF participated in the study. The GH-group consisted of 17 patients of whom 14 completed one year treatment. The no-GH-group consisted of 19 patients, of whom 16 were followed for 6 months, 14 for 12 months and 13 for 18 months. Lumbar spine BMD, total body BMD and body composition were assessed by dual energy X-ray absorptiometry, compared to age-and sex-matched reference values of the same population and expressed as standard deviation scores (SDS). BMD of appendicular bone was measured by quantitative microdensitometry (QMD). Blood samples were obtained to assess bone metabolism and growth factors. Baseline mean lumbar spine and total body BMD SDS of all patients were not significantly different from normal. Mean lumbar spine and total body BMD SDS did not change significantly in the GH-group during GH treatment. The change of QMD at the midshaft during the first 6 months of GH treatment was significantly smaller than during the observation period (P < 0.01). Height SDS and biochemical markers of both bone formation and bone resorption increased significantly during GH treatment; 1,25-dihydroxyvitamin D remained stable. Lean tissue mass increased (P < 0.001) and percentage body fat decreased (P < 0.01) during GH treatment. BMD, the biochemical markers of bone turnover which are independent of renal function, and body composition remained stable in the no-GH-group. Mean lumbar spine and total body BMD of children with chronic renal failure did not differ from healthy controls. The lack of a GH-induced increase in 1,25-dihydroxyvitamin D levels, probably due to treatment with alpha-calcidol, might be linked to the absence of a response in BMD during GH treatment in children with chronic renal failure.
- 1 February 1998
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 83 (2) , 370-373
Bone Mineral Density and Body Composition before and during Treatment with Gonadotropin-Releasing Hormone Agonist in Children with Central Precocious and Early Puberty1
Major changes in bone mineral density (BMD) and body composition occur during puberty. In the present longitudinal study, we evaluated BMD and calculated volumetric BMD [bone mineral apparent density (BMAD)], bone metabolism, and body composition of children (32 girls and 2 boys) with central precocious and early puberty before and during treatment with GnRH agonist (GnRH). Patients were studied at baseline and during treatment for 6 months (n = 34), 1 yr (n = 33), and 2 yr (n = 16). Lumbar spine and total body BMD and body composition were measured with dual-energy x-ray absorptiometry. The variables were compared with age- and sex-matched reference values of the same population and expressed as SD score (SDS). Bone age was assessed. Serum calcium, phosphate, alkaline phosphatase, osteocalcin, the carboxyterminal propeptide of type I collagen (PICP), cross-linked telopeptide of collagen I (ICTP), 1,25 dihydroxyvitamin D and urinary hydroxyproline/creatinine, and calcium/ creatinine ratios were measured. Mean lumbar spine BMD SDS was significantly higher than zero at baseline (P < 0.02) and did not differ from normal, after 2 yr of treatment. Mean spinal BMAD SDS and total body BMD SDS were not significantly different from zero at baseline and had not changed significantly after 2 yr of treatment. During therapy, fat mass and percentage body fat SDS increased, whereas lean tissue mass SDS decreased. Mean lumbar spine BMD and BMAD and total body BMD SDS, calculated for bone age, were all lower than zero at baseline (BMD P < 0.001 and BMAD P < 0.05) and also after 2 yr treatment (respectively, P < 0.001, P < 0.05, and P < 0.01). Biochemical bone parameters were significantly higher than prepubertal values at baseline, and they decreased during treatment. In conclusion, patients with central precocious and early puberty had normal BMD for chronological age but low BMD for bone age, after 2 yr of treatment with GnRH. Bone turnover decreased during treatment. Changes in body composition resembled those seen in patients with GH deficiency.
- 1 February 1998
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 83 (2) , 370-373
Bone Mineral Density and Body Composition before and during Treatment with Gonadotropin-Releasing Hormone Agonist in Children with Central Precocious and Early Puberty1
Major changes in bone mineral density (BMD) and body composition occur during puberty. In the present longitudinal study, we evaluated BMD and calculated volumetric BMD [bone mineral apparent density (BMAD)], bone metabolism, and body composition of children (32 girls and 2 boys) with central precocious and early puberty before and during treatment with GnRH agonist (GnRH). Patients were studied at baseline and during treatment for 6 months (n = 34), 1 yr (n = 33), and 2 yr (n = 16). Lumbar spine and total body BMD and body composition were measured with dual-energy x-ray absorptiometry. The variables were compared with age- and sex-matched reference values of the same population and expressed as SD score (SDS). Bone age was assessed. Serum calcium, phosphate, alkaline phosphatase, osteocalcin, the carboxyterminal propeptide of type I collagen (PICP), cross-linked telopeptide of collagen I (ICTP), 1,25 dihydroxyvitamin D and urinary hydroxyproline/creatinine, and calcium/ creatinine ratios were measured. Mean lumbar spine BMD SDS was significantly higher than zero at baseline (P < 0.02) and did not differ from normal, after 2 yr of treatment. Mean spinal BMAD SDS and total body BMD SDS were not significantly different from zero at baseline and had not changed significantly after 2 yr of treatment. During therapy, fat mass and percentage body fat SDS increased, whereas lean tissue mass SDS decreased. Mean lumbar spine BMD and BMAD and total body BMD SDS, calculated for bone age, were all lower than zero at baseline (BMD P < 0.001 and BMAD P < 0.05) and also after 2 yr treatment (respectively, P < 0.001, P < 0.05, and P < 0.01). Biochemical bone parameters were significantly higher than prepubertal values at baseline, and they decreased during treatment. In conclusion, patients with central precocious and early puberty had normal BMD for chronological age but low BMD for bone age, after 2 yr of treatment with GnRH. Bone turnover decreased during treatment. Changes in body composition resembled those seen in patients with GH deficiency.
- Open Access
- 1 August 1997
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 66 (2) , 232-238
Determinants of body composition measured by dual-energy X-ray absorptiometry in Dutch children and adolescents
Knowledge about body composition is important in metabolic and nutritional studies. In this cross-sectional study the body composition of 403 healthy white Dutch children and adolescents was evaluated by using dual-energy X-ray absorptiometry (DXA). Possible determinants of body composition were analyzed. In 85 subjects the results of bioelectrical impedance analysis (BIA) were compared with DXA. Fat mass, lean tissue mass, and bone mineral content were greater in older boys and girls. Percentage body fat was greater in older girls but not in boys and it was higher in girls than in boys at all ages. From the age of 14 y boys had higher lean tissue mass and bone mineral content than girls. Tanner stage had a significant relation with body composition in both sexes. Percentage body fat was lower in boys in stage 4 than in stage 3 and was higher in consecutive Tanner stages in girls. After adjustment for age, Tanner stage was significantly positively related to lean tissue mass and bone mineral content in boys and girls and to percentage body fat and fat mass in girls. The profession of the parents and the education of the father had a significant negative correlation with percentage body fat and fat mass in girls (P < 0.01). Physical activity was related to lean tissue mass (P = 0.001) but not to fat mass in boys after adjustment for age. A high correlation and a small difference was found between lean body mass by BIA and lean tissue mass by DXA. Body composition in healthy Dutch children and adolescents is related to age, sex, Tanner stage, socioeconomic status, and physical activity.
- 1 August 1997
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 66 (2) , 232-238
Open AccessDeterminants of body composition measured by dual-energy X-ray absorptiometry in Dutch children and adolescents
Knowledge about body composition is important in metabolic and nutritional studies. In this cross-sectional study the body composition of 403 healthy white Dutch children and adolescents was evaluated by using dual-energy X-ray absorptiometry (DXA). Possible determinants of body composition were analyzed. In 85 subjects the results of bioelectrical impedance analysis (BIA) were compared with DXA. Fat mass, lean tissue mass, and bone mineral content were greater in older boys and girls. Percentage body fat was greater in older girls but not in boys and it was higher in girls than in boys at all ages. From the age of 14 y boys had higher lean tissue mass and bone mineral content than girls. Tanner stage had a significant relation with body composition in both sexes. Percentage body fat was lower in boys in stage 4 than in stage 3 and was higher in consecutive Tanner stages in girls. After adjustment for age, Tanner stage was significantly positively related to lean tissue mass and bone mineral content in boys and girls and to percentage body fat and fat mass in girls. The profession of the parents and the education of the father had a significant negative correlation with percentage body fat and fat mass in girls (P < 0.01). Physical activity was related to lean tissue mass (P = 0.001) but not to fat mass in boys after adjustment for age. A high correlation and a small difference was found between lean body mass by BIA and lean tissue mass by DXA. Body composition in healthy Dutch children and adolescents is related to age, sex, Tanner stage, socioeconomic status, and physical activity.